StockNews.com Initiates Coverage on IRIDEX (NASDAQ:IRIX)

Investment analysts at StockNews.com started coverage on shares of IRIDEX (NASDAQ:IRIX) in a report released on Thursday. The brokerage set a “hold” rating on the medical equipment provider’s stock.

IRIDEX Stock Down 2.4 %

Shares of NASDAQ:IRIX opened at $1.64 on Thursday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.85 and a current ratio of 1.54. IRIDEX has a 52-week low of $1.27 and a 52-week high of $3.65. The company has a market capitalization of $27.28 million, a PE ratio of -2.45 and a beta of 0.81. The company has a fifty day moving average of $1.65 and a 200-day moving average of $1.87.

IRIDEX (NASDAQ:IRIX) last issued its earnings results on Tuesday, November 12th. The medical equipment provider reported ($0.12) earnings per share (EPS) for the quarter. IRIDEX had a negative return on equity of 192.95% and a negative net margin of 22.79%. The firm had revenue of $11.58 million during the quarter. During the same period in the previous year, the firm posted ($0.11) earnings per share.

IRIDEX Company Profile

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.